Skip to main
GILD
GILD logo

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 38 analyst ratings
Buy
Strong Buy 26%
Buy 37%
Hold 34%
Sell 0%
Strong Sell 3%

Bulls say

Gilead Sciences reported a positive financial outlook with its liver disease franchise achieving $3 billion in FY24 sales, representing a 9% year-over-year increase, bolstered by the successful launch of Livdelzi. The HIV segment demonstrated robust performance, with sales rising 16% year-over-year to $19.6 billion in FY24, primarily driven by strong demand and favorable market conditions, alongside Descovy's impressive 21% year-over-year growth, exceeding consensus expectations. Additionally, Gilead's oncology portfolio, while facing competitive pressures, still managed a 12% year-over-year growth, reflecting the company's strategic expansions and resilience across its various therapeutic areas.

Bears say

The analysis indicates a negative outlook for Gilead Sciences's stock primarily due to anticipated revenue declines across several key product lines, including Veklury and HIV therapies. Expectations of flat year-over-year revenue and mid-teen percentage declines quarter-over-quarter for FY25, particularly in HIV revenue, contribute to concerns about growth sustainability. Additionally, competitive pressures from new entrants in both the hepatitis B and C markets and challenges in expanding the CAR-T treatment portfolio further exacerbate the potential for underperformance in Gilead’s financial metrics.

Gilead Sciences (GILD) has been analyzed by 38 analysts, with a consensus rating of Buy. 26% of analysts recommend a Strong Buy, 37% recommend Buy, 34% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 38 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.